Industry News Archive

FDA Approves Nivolumab in Combination for Early-Stage NSCLC

On Friday, March 4, 2022, the U.S. Food and Drug Administration approved nivolumab with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

Read the FDA announcement.

Read Bristol Myers Squibb's announcement.

Posted 3/7/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us